BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: The primary objective of this study is to evaluate PFS rate at 9 months of BIBF 1120 in combination with mFolfox6 compared with mFolfox6 combined to bevacizumab in first line patients with metastatic colorectal cancer.
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2072542 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA